Neumora Therapeutics, a clinical-stage biotechnology company based in Watertown, Massachusetts, went public on September 15, 2023, and has a pipeline targeting neuropsychiatric disorders with seven programs. Its lead candidate, navacaprant, is developed for major depressive disorder, along with other candidates for schizophrenia.
Robert A Lenz sold 32,948 shares of NMRA on 12 September at $11.43 per share, worth a total of $377K. They now own 369,993 NMRA shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
